LSBio
PathPlus™ SLC7A11 / XCT Antibody (aa215-229)

Anti-SLC7A11 antibody IHC of human kidney. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 3.75 ug/ml.

PathPlus™ SLC7A11 / XCT Antibody (aa215-229)

Primary AntibodyLSBio Guarantee
Antibody:Goat Polyclonal
Applications:Enzyme-Linked Immunosorbent Assay, Immunofluorescence, Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot
Reactivity:Human, Non-Human Primate
Format:Liquid
See all SLC7A11 / XCT antibodies →
$495.00each
Catalog Number: LS-B4345-50

For bulk orders or custom formulations:

Request a Quote

Overview

Description
XCT antibody LS-B4345 is an unconjugated goat polyclonal antibody to XCT (SLC7A11) (aa215-229) from human. It is reactive with human and monkey. Validated for IF, IHC, Peptide-ELISA and WB. Cited in 1 publication.
Application
ELISA, IF, IHC, IHC-P, WB
Reactivity
Hu, NHP
Intended Use
Research Use Only
Guarantees
This product carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Polyclonal Antibodies
Alternative Names
CCBR1 | Cystine/glutamate transporter | SLC7A11 | XCT | SLC711
Recommended Dilution: IF/ICC
10 µg/ml
Recommended Dilution: IHC-P
3.75 µg/ml
Recommended Dilution: WB
0.03 - 0.3 µg/ml
UniProt Number
Q9UPY5
SwissProt
Q9UPY5

Target

Target
SLC7A11 / XCT
Antigen Species
Human
Specificity
Human SLC7A11.
Epitope
Human SLC7A11.
Gene Name
SLC7A11

Antibody

Host Species
Goat
Clonality
Polyclonal
Origin Species
Human

Immunogen

Immunogen
Peptide with sequence C-KGQTQNFKDAFSGRD, from the internal region of the protein sequence according to NP_055146.1.
Immunogen Type
Peptide

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
TBS, pH 7.3, 0.02% Sodium Azide, 0.5% BSA
Concentration
0.5 mg/mL
Animal Free
No
Carrier-Free
No
Preservative
Yes
Purification Method
Ammonium Sulfate Precipitation

Storage & Handling

Storage Conditions
Aliquot and store at -20°C. Avoid freeze-thaw cycles.
Recommended Storage Buffer
TBS
Increased Expression of System xc- in Glioblastoma Confers an Altered Metabolic State and Temozolomide Resistance. Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. Molecular cancer research : MCR. 2016 December;14:1229-1242. PubMed: 27658422 PMC: PMC6237285

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.